Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Induction immunosuppressant significantly influences post-transplant clinical outcomes, especially according to the immunological status in kidney transplant recipients (KTRs). Recently, protocol biopsies have been performed to predict post-transplant clinical outcomes, but the association between induction immunosuppressant type and pathologic findings remains still uncertain.
We investigated the association between induction immunosuppressive agents and one-year protocol biopsy findings in KTRs with stable allograft function between 2017 and 2023. Post-transplant outcomes and histopathological patterns in one-year protocol biopsies were compared between KTRs who received basiliximab and thymoglobulin.
A one-year protocol biopsy was performed in 88 KTRs (48 from living and 40 from deceased donors). Among them, 45 (51.1%) showed nonspecific changes, 5 (5.7%), borderline, 18 (20.3%), subclinical rejection: 4 (4.5%), acute T-cell mediated rejection (TCMR), 3 (3.4%), chronic active TCMR, 10 (11.4%), acute antibody-mediated rejection (ABMR), 1 (1.1%), chronic active ABMR, 4 (4.5%), de novo glomerulopathy/recurrence of primary disease, 4 (4.5%) calcineurin inhibitor toxicity, 11 (12.5%), interstitial fibrosis and tubular atrophy, and 1 (1.1%), BK virus nephropathy. There was no significant difference of baseline characteristics between basiliximab and thymoglobulin groups. The number of global sclerosis, cg score, ci score, t-IFTA, ct score, cv score, ah score, and aah score was significantly higher in basiliximab group than thymoglobulin group. However, there were no significant differences of the occurrence of de novo donor specific antibody (DSA) and subclinical rejection between them.
Although kidney function is stable within one-year after transplant, protocol biopsies accounts for potential pathological changes. This study showed that induction immunosuppressant type was not significantly associated with the development of de novo DSA and subclinical rejection, but use of basiliximab was associated with more pronounced chronic allograft injury than thymoglobulin.
